Literature DB >> 25333435

Attributable inpatient costs of recurrent Clostridium difficile infections.

Erik R Dubberke1, Eric Schaefer, Kimberly A Reske, Marya Zilberberg, Christopher S Hollenbeak, Margaret A Olsen.   

Abstract

OBJECTIVE: To determine the attributable inpatient costs of recurrent Clostridium difficile infections (CDIs).
DESIGN: Retrospective cohort study.
SETTING: Academic, urban, tertiary care hospital. PATIENTS: A total of 3,958 patients aged 18 years or more who developed an initial CDI episode from 2003 through 2009.
METHODS: Data were collected electronically from hospital administrative databases and were supplemented with chart review. Patients with an index CDI episode during the study period were followed up for 180 days from the end of their index hospitalization or the end of their index CDI antibiotic treatment (whichever occurred later). Total hospital costs during the outcome period for patients with recurrent versus a single episode of CDI were analyzed using zero-inflated lognormal models.
RESULTS: There were 421 persons with recurrent CDI (recurrence rate, 10.6%). Recurrent CDI case patients were significantly more likely than persons without recurrence to have any hospital costs during the outcome period (P < .001). The estimated attributable cost of recurrent CDI was $11,631 (95% confidence interval, $8,937-$14,588).
CONCLUSIONS: The attributable costs of recurrent CDI are considerable. Patients with recurrent CDI are significantly more likely to have inpatient hospital costs than patients who do not develop recurrences. Better strategies to predict and prevent CDI recurrences are needed.

Entities:  

Mesh:

Year:  2014        PMID: 25333435     DOI: 10.1086/678428

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  14 in total

1.  Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital.

Authors:  S M Heimann; J J Vehreschild; O A Cornely; H Wisplinghoff; M Hallek; R Goldbrunner; B W Böttiger; T Goeser; A Hölscher; S Baldus; F Müller; N Jazmati; S Wingen; B Franke; M J G T Vehreschild
Journal:  Infection       Date:  2015-06-30       Impact factor: 3.553

2.  Estimating Local Costs Associated With Clostridium difficile Infection Using Machine Learning and Electronic Medical Records.

Authors:  Theodore R Pak; Kieran I Chacko; Timothy O'Donnell; Shirish S Huprikar; Harm van Bakel; Andrew Kasarskis; Erick R Scott
Journal:  Infect Control Hosp Epidemiol       Date:  2017-11-06       Impact factor: 3.254

Review 3.  Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections.

Authors:  Lynne Vernice McFarland; Metehan Ozen; Ener Cagri Dinleyici; Shan Goh
Journal:  World J Gastroenterol       Date:  2016-03-21       Impact factor: 5.742

4.  Recurrent Clostridium difficile infection among Medicare patients in nursing homes: A population-based cohort study.

Authors:  Marya D Zilberberg; Andrew F Shorr; William M Jesdale; Jennifer Tjia; Kate Lapane
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

5.  Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States.

Authors:  Dongmu Zhang; Vimalanand S Prabhu; Stephen W Marcella
Journal:  Clin Infect Dis       Date:  2018-04-17       Impact factor: 9.079

6.  Retrospective analysis of long-term gastrointestinal symptoms after Clostridium difficile infection in a nonelderly cohort.

Authors:  Tamar F Barlam; Rene Soria-Saucedo; Omid Ameli; Howard J Cabral; Warren A Kaplan; Lewis E Kazis
Journal:  PLoS One       Date:  2018-12-17       Impact factor: 3.240

7.  Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials.

Authors:  Anirban Basu; Vimalanand S Prabhu; Mary Beth Dorr; Yoav Golan; Erik R Dubberke; Oliver A Cornely; Sebastian M Heimann; Alison Pedley; Ruifeng Xu; Mary E Hanson; Stephen Marcella
Journal:  Open Forum Infect Dis       Date:  2018-11-15       Impact factor: 3.835

8.  Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness.

Authors:  Oliver A Cornely; Maureen Watt; Charles McCrea; Simon D Goldenberg; Enrico De Nigris
Journal:  J Antimicrob Chemother       Date:  2018-09-01       Impact factor: 5.790

Review 9.  Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study.

Authors:  Shanshan Zhang; Sarah Palazuelos-Munoz; Evelyn M Balsells; Harish Nair; Ayman Chit; Moe H Kyaw
Journal:  BMC Infect Dis       Date:  2016-08-25       Impact factor: 3.090

10.  Hospital readmission with Clostridium difficile infection as a secondary diagnosis is associated with worsened outcomes and greater revenue loss relative to principal diagnosis: A retrospective cohort study.

Authors:  Marya D Zilberberg; Brian H Nathanson; Stephen Marcella; John Jay Hawkshead; Andrew F Shorr
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.